Increased performance in creating quality products with competitive pricing. Monocent uses state of the art technology to achieve lean production and deliver excellence in diagnostic innovations.
Monocent is a U.S-based IVD company and this is
What We Do
Development
Constant thirst for innovating new products and solutions in the field of diagnostics is embedded within our company’s DNA.
Manufacturing
Based on a strategic calculation of availability, performance and quality we ensure operational excellence and on-time delivery
Distribution
Having local familiarity with governments and regulations, contact networks and field experience, our international sales team is valuable resource for any distributor.
SARS-CoV2 Antigen Rapid Test
Monocent, Inc. has launched and is offering SARS-CoV2 Antigen Rapid test. A qualitative and immunochromatographic in vitro assay for the detection of SARS-CoV2 virus from nasal swab or nasopharyngeal swab obtained from patient with signs and symptoms of respiratory infection.
Monocent's Antigen test can detect presence of SARS-CoV2 viral nucleocapsid (N) protein in nasal or nasopharyngeal specimen at very low concentration without any high dose hook effect. This product has CE-IVD registration and is sold and marketed in EU countries and worldwide. Useful in hard to reach areas without easy access to a laboratory. This product is not for home use.
The demand is quite high for this product. Please submit your inquiry as soon as possible to fit your order through our production capacity and avoid delays.
ELISA
Enzyme-Linked Immunosorbent Assay
RAPID
Lateral Flow Test
CLIA
Chemiluminescence Immunoassay
IFA
Indirect Immunofluorescence Assay
BIOCHEM
Biochemistry
PCR
Reverse Transcription Polymerase Chain Reaction
SEROLOGY
Test Kits
VET
Veterinary Test Kits
WIDE VARIETY OF
Test Systems
Our extensive Test System portfolio includes ELISA assays, Rapid tests, chemiluminescence assays, Serology tests, IFA test systems, Veterinary tests and instrumentation available to laboratories, Hospitals, Research Institutes and distributors worldwide.
ALLERGY
ANEMIA
AUTOIMMUNE DISEASE
BONE METABOLISM
CARDIAC MARKERS
DIABETES
DRUG OF ABUSE
FERTILITY
FOOD
HEPATITIS TESTS
INFECTIOUS DISEASE
NEONATAL
PARASITOLOGY
STEROIDS
THYROID
TUMOR MARKERS
LATEST GROUNDBREAKING PROJECT
HPV+STI Detection Through NGS
Monocent tireless innovation and collaborative work with talented developers and research companies, brings novel solutions to the IVD industry.
One of the most recent projects that Monocent has had the honor of being part of and be instrumental in its validation has to do with revolutionizing HPV and STI detection through Next-Generation Sequencing (NGS) Technology.
Through this method you have the ability to detect 27 HPVs and 13 STIs in one single reaction with a simple workflow. The accuracy and volume of information that this technology can provide, puts it ahead of all its competition. And given its low cost to setup and operate, this technology is the obvious choice for any medium to large size lab.
If you’re interested and like to be involved click below.